| 1 | 18755143 | Ryanodine receptor phosphorylation at Serine 2030, 2808 and 2814 in rat cardiomyocytes. | Biochem Biophys Res Commun | 2008 Nov 7 |
2 |
| 2 | 22487381 | PKA phosphorylation of cardiac ryanodine receptor modulates SR luminal Ca2+ sensitivity. | J Mol Cell Cardiol | 2012 Jul |
4 |
| 3 | 22934575 | Discovery and preclinical pharmacology of a selective ATP-competitive Akt inhibitor (GDC-0068) for the treatment of human tumors. | J Med Chem | 2012 Sep 27 |
2 |
| 4 | 23287563 | Targeting activated Akt with GDC-0068, a novel selective Akt inhibitor that is efficacious in multiple tumor models. | Clin Cancer Res | 2013 Apr 1 |
13 |
| 5 | 24141624 | Evaluation and clinical analyses of downstream targets of the Akt inhibitor GDC-0068. | Clin Cancer Res | 2013 Dec 15 |
4 |
| 6 | 24705351 | Inhibition of Akt reverses the acquired resistance to sorafenib by switching protective autophagy to autophagic cell death in hepatocellular carcinoma. | Mol Cancer Ther | 2014 Jun |
2 |
| 7 | 26617788 | Long noncoding RNA AK056155 involved in the development of Loeys-Dietz syndrome through AKT/PI3K signaling pathway. | Int J Clin Exp Pathol | 2015 |
2 |
| 8 | 27081168 | Differential Receptor Tyrosine Kinase PET Imaging for Therapeutic Guidance. | J Nucl Med | 2016 Sep |
2 |
| 9 | 27797456 | Microsecond molecular dynamics simulations provide insight into the ATP-competitive inhibitor-induced allosteric protection of Akt kinase phosphorylation. | Chem Biol Drug Des | 2017 May |
9 |
| 10 | 27872130 | A First-in-Human Phase I Study of the ATP-Competitive AKT Inhibitor Ipatasertib Demonstrates Robust and Safe Targeting of AKT in Patients with Solid Tumors. | Cancer Discov | 2017 Jan |
9 |
| 11 | 28065668 | Ablation of the cardiac ryanodine receptor phospho-site Ser2808 does not alter the adrenergic response or the progression to heart failure in mice. Elimination of the genetic background as critical variable. | J Mol Cell Cardiol | 2017 Feb |
1 |
| 12 | 28473255 | Inhibition of Akt and other AGC kinases: A target for clinical cancer therapy? | Semin Cancer Biol | 2018 Feb |
1 |
| 13 | 29100327 | Phosphatidylinositol 3-kinase (PI3Kα)/AKT axis blockade with taselisib or ipatasertib enhances the efficacy of anti-microtubule drugs in human breast cancer cells. | Oncotarget | 2017 Sep 29 |
3 |
| 14 | 29408595 | STX3 represses the stability of the tumor suppressor PTEN to activate the PI3K-Akt-mTOR signaling and promotes the growth of breast cancer cells. | Biochim Biophys Acta Mol Basis Dis | 2018 May |
2 |
| 15 | 29417298 | Targeting the PI3K/AKT/mTOR pathway in triple-negative breast cancer: a review. | Breast Cancer Res Treat | 2018 Jun |
1 |
| 16 | 30037818 | Randomized Phase II Study Evaluating Akt Blockade with Ipatasertib, in Combination with Abiraterone, in Patients with Metastatic Prostate Cancer with and without PTEN Loss. | Clin Cancer Res | 2019 Feb 1 |
1 |
| 17 | 30185800 | Ipatasertib, a novel Akt inhibitor, induces transcription factor FoxO3a and NF-κB directly regulates PUMA-dependent apoptosis. | Cell Death Dis | 2018 Sep 5 |
7 |
| 18 | 30385525 | Correction: A First-in-Human Phase I Study of the ATP-Competitive AKT Inhibitor Ipatasertib Demonstrates Robust and Safe Targeting of AKT in Patients with Solid Tumors. | Cancer Discov | 2018 Nov |
2 |
| 19 | 30877085 | Patient-Driven Discovery, Therapeutic Targeting, and Post-Clinical Validation of a Novel <i>AKT1</i> Fusion-Driven Cancer. | Cancer Discov | 2019 May |
3 |
| 20 | 31147675 | FAIRLANE, a double-blind placebo-controlled randomized phase II trial of neoadjuvant ipatasertib plus paclitaxel for early triple-negative breast cancer. | Ann Oncol | 2019 Aug 1 |
5 |
| 21 | 31173106 | Targeting the PI3K/Akt/mTOR pathway with the pan-Akt inhibitor GDC-0068 in PIK3CA-mutant breast cancer brain metastases. | Neuro Oncol | 2019 Nov 4 |
14 |
| 22 | 31316618 | FGFR<sup>3S249C</sup> mutation promotes chemoresistance by activating Akt signaling in bladder cancer cells. | Exp Ther Med | 2019 Aug |
1 |
| 23 | 31558316 | Ipatasertib sensitizes colon cancer cells to TRAIL-induced apoptosis through ROS-mediated caspase activation. | Biochem Biophys Res Commun | 2019 Nov 19 |
9 |
| 24 | 31619255 | Inhaled gold nanoparticles cause cerebral edema and upregulate endothelial aquaporin 1 expression, involving caveolin 1 dependent repression of extracellular regulated protein kinase activity. | Part Fibre Toxicol | 2019 Oct 16 |
3 |
| 25 | 31663655 | PTEN promotes intervertebral disc degeneration by regulating nucleus pulposus cell behaviors. | Cell Biol Int | 2020 Feb |
3 |
| 26 | 31859249 | Discovery of an AKT Degrader with Prolonged Inhibition of Downstream Signaling. | Cell Chem Biol | 2020 Jan 16 |
5 |
| 27 | 32205017 | Antitumor activity of ipatasertib combined with chemotherapy: results from a phase Ib study in solid tumors. | Ann Oncol | 2020 May |
1 |
| 28 | 32294525 | Akt-targeted therapy as a promising strategy to overcome drug resistance in breast cancer - A comprehensive review from chemotherapy to immunotherapy. | Pharmacol Res | 2020 Jun |
2 |
| 29 | 32451180 | Activating AKT1 and PIK3CA Mutations in Metastatic Castration-Resistant Prostate Cancer. | Eur Urol | 2020 Dec |
3 |
| 30 | 32530390 | Combined inhibition of ACK1 and AKT shows potential toward targeted therapy against KRAS-mutant non-small-cell lung cancer. | Bosn J Basic Med Sci | 2021 Apr 1 |
1 |
| 31 | 32737717 | A phase Ib open-label dose escalation study of the safety, pharmacokinetics, and pharmacodynamics of cobimetinib (GDC-0973) and ipatasertib (GDC-0068) in patients with locally advanced or metastatic solid tumors. | Invest New Drugs | 2021 Feb |
1 |
| 32 | 33040459 | EBP2, a novel NPM-ALK-interacting protein in the nucleolus, contributes to the proliferation of ALCL cells by regulating tumor suppressor p53. | Mol Oncol | 2021 Jan |
3 |
| 33 | 33177006 | Durable Clinical Activity to the AKT Inhibitor Ipatasertib in a Heavily Pretreated Patient With an AKT1 E17K Mutant Metastatic Breast Cancer. | Clin Breast Cancer | 2021 Jun |
1 |
| 34 | 33230431 | miR-301a-PTEN-AKT Signaling Induces Cardiomyocyte Proliferation and Promotes Cardiac Repair Post-MI. | Mol Ther Nucleic Acids | 2020 Dec 4 |
2 |
| 35 | 33373654 | A Rho kinase inhibitor (Fasudil) suppresses TGF-β mediated autophagy in urethra fibroblasts to attenuate traumatic urethral stricture (TUS) through re-activating Akt/mTOR pathway: An in vitro study. | Life Sci | 2021 Feb 15 |
3 |
| 36 | 33648537 | Recombinant CCL17-dependent CCR4 activation alleviates neuroinflammation and neuronal apoptosis through the PI3K/AKT/Foxo1 signaling pathway after ICH in mice. | J Neuroinflammation | 2021 Mar 1 |
1 |
| 37 | 33989112 | Protein kinase inhibitors for the treatment of prostate cancer. | Expert Opin Pharmacother | 2021 Oct |
2 |
| 38 | 34049965 | Evaluation of Ipatasertib Interactions with Itraconazole and Coproporphyrin I and III in a Single Drug Interaction Study in Healthy Subjects. | J Pharmacol Exp Ther | 2021 Aug |
8 |
| 39 | 34066055 | Akt Kinase Intervenes in Flavivirus Replication by Interacting with Viral Protein NS5. | Viruses | 2021 May 12 |
1 |
| 40 | 34066144 | Enhanced Antitumor Effect of Trastuzumab and Duligotuzumab or Ipatasertib Combination in HER-2 Positive Gastric Cancer Cells. | Cancers (Basel) | 2021 May 12 |
3 |
| 41 | 34264439 | Final results of the double-blind placebo-controlled randomized phase 2 LOTUS trial of first-line ipatasertib plus paclitaxel for inoperable locally advanced/metastatic triple-negative breast cancer. | Breast Cancer Res Treat | 2021 Sep |
2 |
| 42 | 34359829 | ER+ Breast Cancer Strongly Depends on MCL-1 and BCL-xL Anti-Apoptotic Proteins. | Cells | 2021 Jul 2 |
1 |
| 43 | 34471960 | Single- and multiple-dose pharmacokinetics, potential for CYP3A inhibition, and food effect in patients with cancer and healthy subjects receiving ipatasertib. | Cancer Chemother Pharmacol | 2021 Dec |
2 |
| 44 | 34907082 | Functional Mapping of AKT Signaling and Biomarkers of Response from the FAIRLANE Trial of Neoadjuvant Ipatasertib plus Paclitaxel for Triple-Negative Breast Cancer. | Clin Cancer Res | 2022 Mar 1 |
5 |
| 45 | 35306249 | Ipatasertib (GDC-0068) and erdafitinib co-treatment for inducing mitochondrial apoptosis through Bim upregulation in bladder cancer cells. | Biochem Biophys Res Commun | 2022 May 14 |
1 |
| 46 | 35428895 | Assessment of cytochrome P450 3A4-mediated drug-drug interactions for ipatasertib using a fit-for-purpose physiologically based pharmacokinetic model. | Cancer Chemother Pharmacol | 2022 May |
5 |
| 47 | 35440108 | Distinct resistance mechanisms arise to allosteric vs. ATP-competitive AKT inhibitors. | Nat Commun | 2022 Apr 19 |
1 |
| 48 | 35603567 | Identification of novel natural inhibitors targeting AKT Serine/Threonine Kinase 1 (AKT1) by computational study. | Bioengineered | 2022 May |
1 |